A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies

Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2014.11.529

Related search